Table 3.
Results of a Weibull regression multivariate analysis for factors that contributed to event-free and overall survival in patients with CLL treated with lenalidomide
| Factor | EFS | OS | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Model for TN patients | ||||||
| TP53 aberration | 3.5 | 1.15-10.6 | .023 | 2.62 | 0.44-15.5 | .303 |
| Complex karyotype | 1.57 | 0.54-4.57 | .407 | 0.67 | 0.06-7.9 | .753 |
| IGHV mutated | 0.95 | 0.47-1.93 | .889 | 0.45 | 0.13-1.59 | .889 |
| Model for R/R patients | ||||||
| TP53 aberration | 1.83 | 1.16-2.89 | .008 | 2.1 | 1.21-3.62 | .009 |
| Complex karyotype | 1.39 | 0.86-2.27 | .181 | 2.08 | 1.15-3.76 | .015 |
| SF3B1 | 1.37 | 0.77-2.42 | .278 | 2.52 | 1.33-4.80 | .004 |
| DDX3X | 2.24 | 0.77-6.44 | .133 | 1.1 | 0.33-3.63 | .872 |
| IGHV mutated | 0.72 | 0.42-1.21 | .213 | 0.79 | 0.38-1.63 | .527 |
HR, hazard ratio.